Lilly Is Betting On Byetta LAR
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Lechleiter is “confident” that clinical data expected this quarter on Lilly’s follow-on Byetta LAR will overcome FDA concerns over Byetta.